Clobenpropit: Difference between revisions
Content deleted Content added
No edit summary |
Entranced98 (talk | contribs) +sd |
||
(27 intermediate revisions by 21 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{chembox |
|||
{{Drugbox |
|||
⚫ | |||
⚫ | |||
|ImageSize= |
|||
⚫ | |||
⚫ | |||
|OtherNames= |
|||
<!--Clinical data--> |
|||
|Section1= {{Chembox Identifiers |
|||
| tradename = |
|||
⚫ | |||
| pregnancy_category = |
|||
⚫ | |||
| legal_US = IND |
|||
⚫ | |||
| routes_of_administration = |
|||
}} |
|||
|Section2= {{Chembox Properties |
|||
<!--Pharmacokinetic data--> |
|||
| Formula=C<sub>14</sub>H<sub>17</sub>ClN<sub>4</sub>S |
|||
| bioavailability = |
|||
| MolarMass=308.83 g/mol |
|||
| metabolism = |
|||
| Appearance= |
|||
| elimination_half-life = |
|||
| Density= |
|||
| excretion = |
|||
| MeltingPt= |
|||
| BoilingPt= |
|||
<!--Identifiers--> |
|||
| Solubility= |
|||
⚫ | |||
}} |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
|Section3= {{Chembox Hazards |
|||
| UNII = RKU631JF4H |
|||
| MainHazards= |
|||
| ATC_prefix = None |
|||
| FlashPt= |
|||
| ATC_suffix = |
|||
| Autoignition= |
|||
⚫ | |||
}} |
|||
| IUPHAR_ligand = 1223 |
|||
| ChemSpiderID = 2688 |
|||
| ChEMBL = 14690 |
|||
<!--Chemical data--> |
|||
| C=14 | H=17 | Cl=1 | N=4 | S=1 |
|||
⚫ | |||
}} |
}} |
||
⚫ | '''Clobenpropit''' is a [[H3 antagonist| |
||
⚫ | '''Clobenpropit''' is a [[histamine]] [[H3 antagonist|H<sub>3</sub> receptor antagonist]].<ref name="pmid17537431">{{cite journal | vauthors = Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P | title = The human histamine H3 receptor couples to GIRK channels in ''Xenopus'' oocytes | journal = European Journal of Pharmacology | volume = 567 | issue = 3 | pages = 206–210 | year = 2007 | pmid = 17537431 | doi = 10.1016/j.ejphar.2007.04.032 }}</ref> It has [[neuroprotective]] effects via stimulation of [[GABA]] release in brain cells ''[[in vitro]]''.<ref>{{ cite journal | vauthors = Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z | title = The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons | journal = European Journal of Pharmacology | year = 2007 | volume = 563 | issue = 1–3 | pages = 117–123 | pmid = 17350613 | doi = 10.1016/j.ejphar.2007.01.069 }}</ref> |
||
⚫ | |||
⚫ | |||
{{Reflist}} |
{{Reflist}} |
||
Line 32: | Line 40: | ||
[[Category:H3 receptor antagonists]] |
[[Category:H3 receptor antagonists]] |
||
[[Category:Imidazoles]] |
|||
[[Category:Chloroarenes]] |
|||
{{ |
{{nervous-system-drug-stub}} |
||
{{pharma-stub}} |
Latest revision as of 01:31, 13 November 2022
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H17ClN4S |
Molar mass | 308.83 g·mol−1 |
3D model (JSmol) | |
|
Clobenpropit is a histamine H3 receptor antagonist.[1] It has neuroprotective effects via stimulation of GABA release in brain cells in vitro.[2]
References[edit]
- ^ Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P (2007). "The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes". European Journal of Pharmacology. 567 (3): 206–210. doi:10.1016/j.ejphar.2007.04.032. PMID 17537431.
- ^ Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007). "The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons". European Journal of Pharmacology. 563 (1–3): 117–123. doi:10.1016/j.ejphar.2007.01.069. PMID 17350613.